NRG Oncology Biospecimen Bank

NRG 肿瘤生物样本库

• 批准号: 9250102
• 负责人: RICHARD C JORDAN
• 金额: $ 213.29万
• 依托单位: NRG ONCOLOGY FOUNDATION, INC.
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-04-22 至 2020-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9250102
• 关键词: Adopted; Adoption; Agreement; Aliquot; Bioinformatics; Biological Preservation; Brain; Breast; Cancer Patient; Chest; Clinical; Clinical Oncology; Clinical Treatment; Clinical Trials; Collection; Communities; Data; Development; Disease; Enrollment; Epidemiology; Foundations; Funding; Future; Genomics; Goals; Gynecologic Oncology Group; Head and neck structure; Health; Informatics; Jordan; Link; Lung; Malignant Neoplasms; Methods; National Clinical Trials Network; National Surgical Adjuvant Breast and Bowel Project; Normal tissue morphology; Patients; Performance; Phase; Positioning Attribute; Prediction of Response to Therapy; Process; Protocols documentation; Publications; Radiation Therapy Oncology Group; Reporting; Research; Research Infrastructure; Research Personnel; Resources; Sampling; Science; Services; Site; Specimen; Standardization; System; Translational Research; Treatment outcome; Tumor Markers; Tumor Tissue; United States National Institutes of Health; arm; biobank; cancer care; cancer clinical trial; cancer therapy; data exchange; experience; improved; innovation; interoperability; oncology; operation; outcome forecast; personalized approach; public health relevance; quality assurance; repository; targeted therapy trials; translational scientist; translational study; treatment trial

 DESCRIPTION (provided by applicant): NRG Oncology (NRG) is a newly constituted National Clinical Trials Network (NCTN) group created through the coordinated efforts and scientific merger of the National Surgical Adjuvant Breast and Bowel Project (NSABP), the Radiation Therapy Oncology Group (RTOG), and the Gynecologic Oncology Group (GOG). The NRG Oncology Biospecimen Bank (NRG-BB) will be formed from the three legacy biospecimen resources of the RTOG, GOG and NSABP into a single repository for all biospecimens collected as part of NRG Oncology clinical trials. NRG Oncology and the NCI have agreed to enroll up to 5,099 patients per year in future NCI-funded NRG-sponsored cancer clinical trials. We will collect, process and manage biospecimens from patients enrolled in Phase II & III clinical treatment trials to maintain an accurate and effective repository of tumor and normal tissues with associated clinical, epidemiologic, and descriptive biospecimen information, for use in trial-related activities and future translational science projects. The NRG-BB will maximize the quality and quantity of biospecimens and their derivatives through the utilization of standardized and optimal preservation, storage, quality assurance and distribution methods. We will market and distribute de-identified samples in a standardized and equitable manner to all qualified investigators both within and outside NRG Oncology by utilizing Biospecimen IT Navigator and NCTN Biospecimen "front door" services. Working with the biobanks from other NCTN groups and the Group Banking Committee of the NCI, we will harmonize biospecimen activities and processes. Finally, we will develop distributed infrastructure to support and/or perform innovative genomic analyses for patient assignment to multi-arm targeted therapy trials conducted by NRG Oncology. Robust informatics is required to allow translational scientists to know what is available within the NRG-BB and to equitably distribute biospecimens to the translational science community both within and outside NRG Oncology. We have anticipated this need by already harmonizing and consolidating our IT resources using a common Specimen Tracking and Reporting System (STARS) bioinformatics platform. This adoption of a common IT platform across the 3 legacy biospecimen banks has permitted an improved service level for the group, interoperability and freely exchangeable data with our NRG-BB partners and opportunities to enhance our links with the SDMC. Moreover, this new platform has permitted better external linkages with the Group Banking Committee, the NCI and with the Navigator and Front Door project.

 描述(由申请人提供)：NRG肿瘤学(NRG)是一个新成立的国家临床试验网络(NCTN)小组，由国家外科辅助乳肠计划(NSABP)、放射治疗肿瘤组(RTOG)和妇科肿瘤组(GOG)协调努力和科学合并而成。NRG肿瘤学生物谱库(NRG-BB)将由RTOG、GOG和NSABP三个遗留生物谱系资源组成，成为作为NRG肿瘤学临床试验一部分收集的所有生物谱系的单一储存库。NRG肿瘤学和NCI已经同意在未来NCI资助的NRG赞助的癌症临床试验中每年招募多达5099名患者。我们将收集、处理和管理参加第二阶段和第三阶段临床治疗试验的患者的生物标本，以维护准确有效的肿瘤和正常组织以及相关临床、流行病学和描述性生物标本信息的存储库，用于试验相关活动和未来的翻译科学项目。NRG-BB将通过使用标准化和最佳的保存、储存、质量保证和分配方法，最大限度地提高生物检疫剂及其衍生物的质量和数量。我们将利用BiOspecimen IT Navigator和NCTN Biosecimen“前门”服务，以标准化和公平的方式向NRG肿瘤学内部和外部的所有合格研究人员销售和分发未鉴定的样本。我们将与其他NCTN组织的生物库和NCI的集团银行委员会合作，协调生物检疫活动和进程。最后，我们将开发分布式基础设施，为NRG肿瘤学进行的多臂靶向治疗试验的患者分配支持和/或执行创新的基因组分析。需要强大的信息学来让翻译科学家知道NRG-BB中有什么可用，并将生物样本公平地分配给NRG肿瘤学内外的翻译科学界。我们已经通过使用通用标本跟踪和报告系统(STAR)生物信息学平台来协调和整合我们的IT资源，从而预见到了这一需求。通过在三家传统生物样品银行之间采用一个通用的IT平台，提高了集团的服务水平，提高了与NRG-BB合作伙伴的互操作性和可自由交换的数据，并提供了加强我们与SDMC联系的机会。此外，这一新平台还加强了与集团银行委员会、国家保险公司以及导航器和前门项目的外部联系。